Xenon Pharmaceuticals
XENE
25 hedge funds and large institutions have $39.9M invested in Xenon Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 1 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0% more funds holding
Funds holding: 25 → 25 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
14% less capital invested
Capital invested by funds: $46.5M → $39.9M (-$6.56M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.67M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$719K |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$686K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$296K |
| 5 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
+$43.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.32M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$175K |
| 3 |
VAM
Visium Asset Management
New York
|
-$144K |
| 4 |
Renaissance Technologies
New York
|
-$38.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$10.9K |
XENE Hedge Fund Activity: Q1 2016 in Review
25 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2016, worth a combined $39.9M — down 14% from $46.5M a quarter earlier.
Fund positioning in XENE was balanced in Q1 2016: 1 fund opened new positions, 1 closed out, 7 added to existing stakes and 6 trimmed.
The largest buyer was BVF Inc, adding an estimated $4.67M. The largest seller was Fidelity Investments, exiting entirely with an estimated $7.32M sold.
- 25 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $39.9M of Xenon Pharmaceuticals stock for Q1 2016, down 14% quarter-over-quarter.
- 1 fund opened new Xenon Pharmaceuticals positions in Q1 2016 and 1 closed out, a net change of 0 holders.
- The largest Xenon Pharmaceuticals buyer in Q1 2016 was BVF Inc, an estimated $4.67M added.
- The largest Xenon Pharmaceuticals seller in Q1 2016 was Fidelity Investments, an estimated $7.32M sold.
Based on aggregated 13F filings for Q1 2016.